Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
168.6 USD | +1.89% | +7.84% | +8.78% |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
Jun. 06 | AbbVie's ovarian cancer therapy succeeds in mid-stage trial | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.78% | 298B | |
+43.64% | 754B | |
+39.42% | 630B | |
-6.58% | 352B | |
+19.72% | 331B | |
+11.92% | 217B | |
-2.62% | 216B | |
+0.03% | 163B | |
+6.13% | 164B | |
+1.39% | 124B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Deutsche Bank Raises AbbVie Price Target to $170 From $150, Maintains Hold Rating